Cancer Registry Software Market By Type (Standalone Software and Integrated Software), By Deployment Model (On-premise and Cloud-based), By Database (Commercial Databases and Public Databases), By Functionality (Cancer Reporting to Meet State & Federal Regulations, Patient Care Management, Product Outcome Evaluation, and Medical Research & Clinical Studies), By End-user (Government Organizations & Third-party Administrators (TPAS), Hospitals & Medical Practices, Pharmaceutical, Biotechnology, & Medical Device Companies, Private Payers, and Research Centers), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Cancer Registry Software Market Size is expected to be worth around USD 205.7 million by 2033 from USD 78.6 million in 2023, growing at a CAGR of 10.1% during the forecast period 2024 to 2033.

The cancer registry software market is experiencing significant growth driven by several factors. First, the increasing prevalence of cancer and favorable government initiatives play a key role. Government organizations worldwide are digitizing and integrating healthcare systems, including developing computerized disease registries to monitor cancer burden and evaluate prevention and control efforts.

Additionally, interoperability standards and data-sharing initiatives contribute to the expansion of cancer registry software. Emerging markets, particularly in Asia Pacific and Latin America, offer untapped opportunities for market growth. As the global cancer burden continues to rise, demand for cancer registry software will remain strong, aiding in trend identification and treatment strategies.

For instance, as per the estimates from the IARC (International Agency for Research on Cancer) updated in July 2021, the global count of cancer cases is projected to have 27.5 million new cases of cancer and 16.3 million cancer deaths worldwide by 2040. Such high numbers are set to increase the need for cancer registry software. Collaborations among software vendors, healthcare providers, and research institutions further accelerate innovation in this field.

Key Takeaways

• In 2023, the market for Cancer Registry Software generated a revenue of USD 78.6 million, with a CAGR of 10.1%, and is expected to reach USD 205.7 million by the year 2033.
• The type segment is divided into standalone software and integrated software, with integrated software taking the lead in 2023 with a market share of 54.2%.
• Considering the deployment model, the market is divided into on-premise and cloud-based. Among these, the cloud-based segment held a significant share of 64.2%.
• Furthermore, concerning the database segment, the market is segregated into commercial databases and public databases. The commercial databases sector stands out as the dominant player, holding the largest revenue share in the Cancer Registry Software market.
• Considering functionality, the market is divided into cancer reporting to meet state & federal regulations, patient care management, product outcome evaluation, and medical research & clinical studies. Among these, patient care management held a significant share.
• The end-user segment is segregated into government organizations & third-party administrators (TPAS), hospitals & medical practices, pharmaceutical, biotechnology, & medical device companies, private payers, and research centers, with the government organizations & third-party administrators (TPAS)segment leading the market, holding a revenue share.
• North America led the market by securing a market share of 35.6% in 2023.

Type Analysis

The integrated software segment led in 2023, claiming a market share of 54.2% owing to Integrated software being a lucrative segment due to the developing nature of the market. It addresses the need to optimize processes, improve workflows, and manage physician workloads. Factors driving growth include government emphasis on coordinated care, population health management, and healthcare cost containment. Standalone software with automated features reduces IT overhead costs.

Notably, CAN REG 5, an open-source standalone software introduced by the World Health Organization (WHO), offers features such as automated system backup & data restoration. Integrated software is expected to experience significant growth. Its integration with regional oncology networks allows tracking of affected geographic locations and assessment of clinical interventions. In the future, this integration will provide valuable insights into disease burden and treatment program effectiveness. Combining screening archives further enhances evaluation techniques, contributing to market growth during the assessment period.

Deployment Model Analysis

The cloud-based held a significant share of 64.2% due to reduced installation costs and lower IT overhead. Cloud-based software primarily offers a platform-as-a-service solution, with key benefits including real-time data analysis and adherence to standard guidelines.

Companies are actively enhancing data security within this model. This is anticipated to create lucrative prospects for the market during the forecast period.

Database Analysis

The commercial database segment had a tremendous growth rate, with a major revenue share as it has better data privacy in comparison to the public data sector. The commercial database follows the governmental coding requirements. It aids in providing well-organized and clear information.

Commercial technologies support data transmission amongst government research agencies such as the Centers for Disease Control & Prevention (CDC) and central cancer registries.

Functionality Analysis

The patient care management segment grew at a substantial rate, generating a significant revenue portion due to the increasing need for effective cancer care coordination and management. This segment enables healthcare providers to track patient diagnoses, treatments, and outcomes, facilitating personalized care and improving patient engagement.

This provides numerous medical services that aid people in keeping a proper health record. This ranges from scheduling primary care appointments to chronic illness management and short-term case management.

End-user Analysis

The government organizations & third-party administrators (TPAS) segment had a tremendous growth rate, with a large revenue share owing to the increasing demand for cancer data management and analysis. Government initiatives such as Surveillance, Epidemiology, and End Results (SEER) program, drive the adoption of cancer registry software.

Third-party administrators such as insurance companies and research organizations also require cancer registry software for data analysis and reporting. As a result, this segment is anticipated to experience significant growth during the forecast period.

Key Market Segments

By Type

• Standalone Software
• Integrated Software

By Deployment Model

• On-premise
• Cloud-based

By Database

• Commercial Databases
• Public Databases

By Functionality

• Cancer Reporting to Meet State & Federal Regulations
• Patient Care Management
• Product Outcome Evaluation
• Medical Research & Clinical Studies

By End-User

• Government Organizations & Third-party Administrators (TPAS)
• Hospitals & Medical Practices
• Pharmaceutical, Biotechnology, & Medical Device Companies
• Private Payers
• Research Centers

Drivers

Growing Prevalence of Cancer

The growing occurrence of cancer drives the cancer registry software market by increasing the demand for efficient data management and analysis solutions. As cancer cases rise, healthcare organizations and researchers need advanced software to collect, store, and analyze vast amounts of data. Cancer registry software helps track patient outcomes, treatment patterns, and survival rates, informing research and improving care.

Consequently, with the growing number of cancer cases across the globe, the market is expected to experience substantial propulsion in the years to come. As per the data published by the American Cancer Society Journal in January 2024, around 2,001,140 new cases of cancer are expected to emerge in the year 2024. Furthermore, approximately 611,720 deaths caused by cancer are estimated to occur in the US.

Restraints

Increasing Risks Related to Privacy and Data Security

Health data stored in cancer patient databases or registries includes various demographic and personal factors, such as marital status, socioeconomic status, mental and emotional stability, physical abilities, age, gender, and race. Unfortunately, patient information can be exposed in situations like data breaches, which occur in about 30% of healthcare industry breaches.

Factors contributing to breaches include inadequate internal patient information control, lack of top management support, outdated rules and procedures, and insufficient staff training. Balancing privacy concerns with administrative needs remains a critical challenge.

Opportunities

Rising Accountable Care Organizations (ACOs)

ACOs focus on coordinated care and effective chronic disease management. These organizations receive payments based on achieving healthcare quality goals and outcomes, resulting in cost savings for the overall medical care delivery system. To enhance patient care, ACOs must have insights into their population, providers, patients, and care status.

Cancer patient registries tailored to specific populations play a crucial role in supporting ACOs and other accountable care arrangements, adapting to evolving requirements. For 2023 the ACO REACH Model has 132 Accountable Care Organizations with 131,772 organizations and healthcare providers providing care to around 2.1 million beneficiaries.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors exert a significant influence on the Cancer Registry Software market, shaping its growth trajectory and dynamics. Macroeconomic factors like government funding and investments in healthcare infrastructure positively impact the cancer registry software market, driving growth and innovation. Economic growth and stability lead to increased healthcare spending, benefitting the market. Geopolitical factors such as trade agreements and partnerships facilitate international collaboration and data sharing, expanding market opportunities.

Latest Trends

High Number of Clinical Trials & Cancer Registries

Pharmaceutical companies and research institutes conduct clinical trials to explore novel cancer treatment approaches. These trials involve in-depth analyses of registry data to monitor cancer causes and potential cures. During phase III and IV clinical trials, cancer registries serve as valuable follow-up sources. Developing advanced cancer registry software enhances data quality for both public and private registry organizations, driving overall market growth.

As of January 2022, more than 98% of cancer registries funded by the National Program of Cancer Registries (NPCR) utilize at least one Registry Plus product. Additionally, over half of these registries employ two or more Registry Plus products. These tools have become a standard platform for cancer registries, aiding in meeting NPCR’s requirements for electronic data exchange and enhancing registry operations through automation.

Regional Analysis

North America is leading the Cancer Registry Software Market

North America dominated the market with the highest revenue share of 35.6% owing to the high cancer burden, well-established healthcare infrastructure, government support, and a forward-thinking approach to technology adoption. The region’s robust healthcare system, coupled with significant government funding, creates an environment conducive to adopting modern technologies like cancer registry software.

Key areas of focus in North America include integrating with Electronic Health Records (EHRs), leveraging AI-powered analytics, and advancing personalized treatment through comprehensive data insights. Integration with EHRs streamlines patient records and enhances overall healthcare delivery efficiency.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

The Asia-Pacific region is projected to be the fastest-growing market for cancer registry software. This growth is driven by several factors, including the increasing prevalence of cancer, higher healthcare spending, proactive government initiatives to strengthen healthcare infrastructure, and the rapid adoption of digital health technologies.

Digital tools, including cancer registry software, facilitate efficient data management, enhance collaboration among healthcare professionals, and support evidence-based decision-making. Lifestyle changes, longer life expectancy, and environmental factors contribute to the rising cancer incidence in the Asia-Pacific region, emphasizing the need for robust cancer management and research efforts.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the Cancer Registry Software market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. These key players focus on enhancing software capabilities, user experience, and analytics.

They expand reach through partnerships with healthcare organizations, research institutions, and technology companies. Furthermore, they provide high-quality support, training, and consulting services to ensure customer satisfaction and loyalty.

Top Key Players in the Cancer Registry Software Market

• Elekta
• C/NET Solutions
• Electronic Registry Systems Inc.
• Onco Inc.
• McKesson Corporation
• Siemens Healthineers
• IBM Corporation
• Ordinal data, Inc.
• Conduent, Inc.
• Roche
• NeuralFrame, Inc

Recent Developments

• In May 2022, Roche and Kaiku Health entered a strategic collaboration for digital patient monitoring and management (DPMM). Their collaboration aims to deploy digital tools for real-time management of symptoms by Health Care Providers (HCPs) and patients, enhance patient support, and deliver personalized cancer care to clinics and patients worldwide. Cancer registry software plays a vital role in this initiative.
• In March 2022, Elekta announced that the NHSSC (National Health Service Supply Chain) had procured multiple licenses for Elekta’s ProKnow software solution. This platform analyzes and centralizes radiotherapy data in a secure and scalable manner, making it accessible to radiation oncology facilities across NHS England (NHSE). The utilization of cancer registry software is integral to this effort.

Report Scope